No Data
No Data
China's Medical Device Market Value Hits $179B, 90th CMEF in Shenzhen to Feature a Plethora of Technological Products
Sinolink Securities: The pharmaceutical sector is expected to see an improvement in market conditions in the third quarter, and overall growth expectations for the second half of the year are optimistic.
Sinolink Securities released a research report stating that considering the improvement in the medical insurance settlement cycle, the expectation of policy improvement, and the recovery performance of the industry, as well as the fact that institutional medicine hold positions are at a low level, the medical sector will usher in an improved market situation in Q3.
Hong Kong stocks surge | Guichuang Tongqiao-B (02190) rises more than 6%. The company has entered the stage of intensive product approval, and institutions predict that the new product will continue to be released throughout the year.
Zh Tong Finance APP learned that Gui Chuang Tong Qiao - B (02190) rose more than 6%, as of the release, up 6.41%, reported HKD 10.96, with a turnover of HKD 123 million. On the news front, Gui Chuang Tong Qiao - B issued an announcement that the ZYLOX Unicorn vascular suture device independently developed by the group has recently been approved for listing by the National Medical Products Administration, marking that domestic brands have broken the market monopoly of imported brands in the solution of vascular puncture site suture. Huaan Securities' previous research report pointed out that the company's platformization advantage has initially shown its effects and has entered the stage of intensive product approval (16 new products in 2023 alone, 24-year
Guichuangtong Bridge-B (02190): The National Medical Products Administration has approved the listing of ZYLOX Unicorn vascular suture device.
Guichuangtongqiao-B (02190) announced that ZYLOX Unicorn, independently developed by the group, has been released...
Express News | Zylox-Tonbridge Medical Technology - Nmpa China Gave Marketing Approval for Zylox Unicorn Suture-Mediated Closure System
[Brokerage Focus] Huaan Securities initiates buy rating for Guichuangqiao (02190), expected to continue new product releases and achieve overall profitability this year.
Jingu Finance News | Huaan Securities issued a research report, indicating that Guichuang Tongqiao (02190) covers two high-potential tracks of neural intervention and peripheral intervention. The management team has a R&D background, mastered the core technology, and continuously provides stable and high-quality products, committed to providing a comprehensive product ecosystem in the field of neural and peripheral interventions; the company's platform advantages are starting to take effect, entering the stage of intensive product approvals (only 16 new products in 2023 and 7 new products in 2024), as of May 2024, the company has accumulated 43 products approved for marketing by NMPA and 8 products approved for CE, covering Germany and Italy.
No Data